Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Advertisement

Close

AACR Journals
For Authors
About Us
Article Collections
COVID-19
Webinars

header search

search input Search input auto suggest

Search

Advanced Search

Menu

About
Articles
First Disclosures
For Authors
Alerts
News
COVID-19
Webinars

Skip Nav Destination

Current Issue

Volume 21,

Issue 9

1 September 2022

View This Issue

About the Journal

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.. Read More About the Journal

Editor-in-Chief

Beverly A Teicher

View Full Editorial Board

Impact Factor

6.009

SUBMIT TO JOURNAL

Featured Articles

YES1: A Novel Therapeutic Target and Biomarker in Cancer

Irati Garmendia, et al.

LARGE MOLECULE THERAPEUTICS

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

Andrea T. Hooper, et al.

SMALL MOLECULE THERAPEUTICS

PH-Binding Motif in PAR₄ Oncogene: From Molecular Mechanism to Drug Design

Jeetendra Kumar Nag, et al.

Trending - Altmetric

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

Last mentioned on Wednesday October 5 2022

p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas

Last mentioned on Tuesday October 4 2022

Demonstration of the antitumor activity of the INKT agonist ABX196, a novel enhancer of cancer immunotherapy, in melanoma and hepatocarcinoma mouse models

Last mentioned on Thursday October 6 2022

Inhibition of NF-κB DNA binding suppresses myeloma growth via intracellular redox and tumor microenvironment modulation

Last mentioned on Tuesday October 4 2022

YES1: A Novel Therapeutic Target and Biomarker in Cancer

Last mentioned on Wednesday October 5 2022

Latest
Most Read
Most Cited

Response to BRAF targeted therapy is enhanced by co-targeting VEGFRs or WNT/β-Catenin signaling in BRAF-mutant colorectal cancer models

NOTCH signaling limits the response of Low Grade Serous Ovarian Cancers to MEK inhibition

External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer.

Demonstration of the antitumor activity of the INKT agonist ABX196, a novel enhancer of cancer immunotherapy, in melanoma and hepatocarcinoma mouse models

Tweets by MCT_AACR

Issues
Online First
News

Twitter

Online ISSN 1538-8514
Print ISSN 1535-7163

AACR Journals

Blood Cancer Discovery
Cancer Discovery
Cancer Epidemiology, Biomarkers, & Prevention
Cancer Immunology Research
Cancer Prevention Research
Cancer Research
Cancer Research Communications
Clinical Cancer Research
Molecular Cancer Research
Molecular Cancer Therapeutics

Info for Advertisers
Info for Librarians
Privacy Policy

Twitter
LinkedIn
Facebook
Youtube

Copyright © 2022 by the American Association for Cancer Research.

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.

Accept